Sanofi and Lexicon’s Zynquista (sotagliflozin) Receive EU’s MAA to Treat Type-1 Diabetes in Adults

Shots:

• The authorization is based on inTandem study consisting of three P-III trials assessing sotagliflozin (200/400 mg) vs insulin as monothx in 3000 adults with inadequately controlled T1D
• The study resulted reduction in average blood sugar (HbA1c), body weight, systolic blood pressure, improvement of time in target blood sugar range, patient-reported outcomes within 24 weeks
• Zynquista (sotagliflozin,PO) is an inhibitor of SGLT1 and SGLT2 proteins and is being evaluated in a program of 11 trials for T2D in adults. In Nov,2015 Lexicon and Sanofi collaborated to develop and commercialize sotagliflozin to treat diabetes

Click here to read full press release/ article | Ref: Sanofi| Image: Investors